Menu
Menu
What does it take to ask one question — *how do you free software from hardware?* — and end up reshaping the entire computing industry? In this episode of Decoded, Dr. Jurgi Camblong speaks with Edouard Bugnion, co-founder of VMware and Vice President for Innovation and Impact at EPFL, the Swiss Federal Institute of Technology in Lausanne.
VMware didn't just build a product. It built the foundation on which the modern cloud was built — and was acquired by Broadcom in 2023 for $69 billion. From a childhood in Neuchâtel to a PhD at Stanford, from research lab to billion-dollar company, and back to Switzerland as a professor and public advisor, Edouard has spent his career at the precise intersection of deep science and real-world impact.
You'll hear how a single idea about separating software from hardware gave birth to an industry, what the dot-com crash taught him about building through uncertainty, the three factors he believes determine whether a company succeeds or fails, why the energy cost of AI is a problem that can't be wished away, and what it actually means to be responsible when innovation moves faster than society can keep up. This episode is about what happens when a scientist becomes a builder, and why the most important question in technology right now may not be *what can AI do* — but *what should it do.*
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
